Remifentanil and Glycemic Response in Cardiac Surgery

Completed · Phase 4

Conditions studied: Heart Diseases, Hyperglycemia

In brief

This study evaluates the effect of using remifentanil during cardiopulmonary bypass surgery to supress the hyperglycemic response in perioperative period. Half of the participants will receive continuous intravenous remifentanil during surgery, while the other half will receive intermittent intravenous fentanyl during surgery. Intermittent intravenous fentanyl administration is this institution's standard of care.

Key facts

Study ID

NCT02349152

Run by

Kathirvel Subramaniam

People needed

116

Starts

2016-01-01

Expected to finish

2017-12-01

Last updated by the study team

2020-04-21

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Open cardiac surgery through sternotomy approach (coronary artery bypass, valve surgery, and any other open heart surgeries)
• Surgery with use of cardiopulmonary bypass
• Patients over 18 years of age
• Both female and male genders
• All races

You may not qualify if…

• Minimally invasive heart surgery through thoracotomy approach
• Patients receiving regional analgesia such as intrathecal morphine
• Patients undergoing procedures under deep hypothermic circulatory arrest
• Patients with active infections such as acute infective endocarditis
• Emergency surgery
• Patients undergoing transplantations and ventricular assist device insertion
• Patients on any mechanical circulatory support preoperatively
• Patient's refusal
• Allergy to remifentanil
• Positive pregnancy test
• Morbid obesity
• End stage liver and kidney disease

Where it is running

• UPMC Presbyterian Hospital — Pittsburgh, Pennsylvania, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.